Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

Completed

Brief Summary: This laboratory-based substudy of an effectiveness trial of two Hepatitis B vaccines in HIV-negative youths is being done to evaluate the genetic contribution to the individualized immune response.

Detailed Description: This laboratory-based substudy of ATN 024 and 025 will evaluate the genetic contribution to highly individualized immune responses to hepatitis B vaccine in individuals and confirm the correlation of specific human leukocyte antigen (HLA) alleles and haplotypes with Hepatitis B Virus (HVB) antibody concentrations and antibody decay kinetics in vaccinated adolescents. Approximately 5 ml of whole blood will be collected from study participants at the time of the week 28 visit or at any subsequent study visit or clinic visit following successful completion of the week 28 visit. Peripheral blood mononuclear cells will be obtained and QIA amp Blood kit will be used to extract high-quality genomic DNA for polymerase chain reaction-based genotyping by the PEII laboratory.

The study is expected to be available for the duration of the parent studies which is approximately 2 years. This study requires one visit that may be arranged to coincide with a study or routine clinic visit. There are no follow up visits.

Recruitment & Eligibility

Inclusion Criteria

Subjects currently enrolled in ATN 024 or ATN 025 are eligible for enrollment in ATN 052 beginning at or following completion of the week 28 visit.
Subjects previously enrolled in ATN 024 or ATN 025 are eligible for enrollment in ATN 052, unless the subject was prematurely discontinued from the study prior to the first post-vaccination serology assessment which is performed at week 28.
Current pregnancy is permitted.
A signed informed assent/consent must be obtained from the subject.
Written parental or guardian permission must be obtained where required by the institutional review board/ethics committee (IRB/EC).

Exclusion Criteria

Inadequate post-vaccination serology evaluation in ATN 024 or ATN 025.
Unable to obtain informed consent and/or parental/legal guardian permission where required by the local IRB/EC.

Primary Outcome Measures

Name	Time	Method
To confirm the correlation of HLA-DRB1 and HLA-DQB1 alleles and haplotypes with HBV antibody concentrations and antibody decay kinetics in vaccinated adolescents.	Specimen obtained at or after the first post- vaccination serology visit.

Secondary Outcome Measures

Name	Time	Method
To compare the strength of genetic and non-genetic associations with specific antibody responses following HBV vaccination.	Specimen obtained at or after the first post-vaccination serology visit.
To determine if other genetic variations (768 single nucleotide polymorphisms (SNP) in about 50 genes) in the immune response pathways can confer additional effects on immune responses to hepatitis B vaccination.	Specimen obtained at or after the first post-vaccination serology visit.
To explore similarities and differences in genetic associations between HIV-positive and HIV-negative cohorts.	Specimen obtained at or after the first post-vaccination serology visit.

Locations (4): Children's Hospital of Los Angeles
🇺🇸
Los Angeles, California, United States
Children's Hospital National Medical Center
🇺🇸
Washington, District of Columbia, United States
University of California at San Francisco
🇺🇸
San Franciso, California, United States
University of Southern Florida College of Medicine
🇺🇸
Tampa, Florida, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial